Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy

Shendure, 2017, DNA sequencing at 40: past, present and future, Nature, 550, 345, 10.1038/nature24286 Elkon, 2017, Characterization of noncoding regulatory DNA in the human genome, Nat. Biotechnol., 35, 732, 10.1038/nbt.3863 Ben-David, 2018, Genetic and transcriptional evolution alters cancer cell line drug response, Nature, 560, 325, 10.1038/s41586-018-0409-3 Siegel, 2018, Cancer statistics, 2018, CA Cancer J. Clin., 68, 7, 10.3322/caac.21442 Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912 Tirosh, 2016, Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, Science, 352, 189, 10.1126/science.aad0501 Aronson, 2015, Building the foundation for genomics in precision medicine, Nature, 526, 336, 10.1038/nature15816 Kyrochristos, 2019, Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy, Med. Res. Rev., 39, 1205, 10.1002/med.21549 Roukos, 2017, Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine, Drug Discov. Today, 22, 1148, 10.1016/j.drudis.2017.03.014 Lesterhuis, 2017, Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity, Nat. Rev. Drug Discov., 16, 264, 10.1038/nrd.2016.233 Letai, 2017, Functional precision cancer medicine-moving beyond pure genomics, Nat. Med., 23, 1028, 10.1038/nm.4389 Friedman, 2015, Precision medicine for cancer with next-generation functional diagnostics, Nat. Rev. Cancer, 15, 747, 10.1038/nrc4015 Haendel, 2018, Classification, ontology, and precision medicine, N. Engl. J. Med., 379, 1452, 10.1056/NEJMra1615014 Yates, 2015, Subclonal diversification of primary breast cancer revealed by multiregion sequencing, Nat. Med., 21, 751, 10.1038/nm.3886 Hata, 2016, Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nat. Med., 22, 262, 10.1038/nm.4040 Marusyk, 2014, Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity, Nature, 514, 54, 10.1038/nature13556 Puram, 2017, Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer, Cell, 171, 1611, 10.1016/j.cell.2017.10.044 Ziogas, 2018, Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology, Drug Discov. Today, 23, 1848, 10.1016/j.drudis.2018.07.008 O’Leary, 2018, The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial, Cancer Discov., 8, 1390, 10.1158/2159-8290.CD-18-0264 Nowell, 1976, The clonal evolution of tumor cell populations, Science, 194, 23, 10.1126/science.959840 Fidler, 1977, Metastasis results from preexisting variant cells within a malignant tumor, Science, 197, 893, 10.1126/science.887927 Martin, 2017, Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, Phase 3 trial, Lancet Oncol., 18, 1688, 10.1016/S1470-2045(17)30717-9 von Minckwitz, 2017, Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, N. Engl. J. Med., 377, 122, 10.1056/NEJMoa1703643 Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, Phase 3 trial, Lancet, 389, 1011, 10.1016/S0140-6736(16)32409-6 Rockman, 2008, Reverse engineering the genotype-phenotype map with natural genetic variation, Nature, 456, 738, 10.1038/nature07633 Greaves, 2012, Clonal evolution in cancer, Nature, 481, 306, 10.1038/nature10762 Klein, 2013, Selection and adaptation during metastatic cancer progression, Nature, 501, 365, 10.1038/nature12628 Schmitt, 2016, The influence of subclonal resistance mutations on targeted cancer therapy, Nat. Rev. Clin. Oncol., 13, 335, 10.1038/nrclinonc.2015.175 Jamal-Hanjani, 2017, Tracking the evolution of non-small-cell lung cancer, N. Engl. J. Med., 376, 2109, 10.1056/NEJMoa1616288 Gerlinger, 2014, Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing, Nat. Genet., 46, 225, 10.1038/ng.2891 Furuta, 2017, Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors, J. Hepatol., 66, 363, 10.1016/j.jhep.2016.09.021 Suzuki, 2015, Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment, Genome Biol., 16, 66, 10.1186/s13059-015-0636-y Baslan, 2015, Optimizing sparse sequencing of single cells for highly multiplex copy number profiling, Genome Res., 25, 714, 10.1101/gr.188060.114 Wang, 2014, Clonal evolution in breast cancer revealed by single nucleus genome sequencing, Nature, 512, 155, 10.1038/nature13600 Findlay, 2016, Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy, Nat. Commun., 7, 11111, 10.1038/ncomms11111 Faltas, 2016, Clonal evolution of chemotherapy-resistant urothelial carcinoma, Nat. Genet., 48, 1490, 10.1038/ng.3692 Murugaesu, 2015, Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy, Cancer Discov., 5, 821, 10.1158/2159-8290.CD-15-0412 Kim, 2015, Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity, Clin. Cancer Res., 21, 4461, 10.1158/1078-0432.CCR-14-2413 Strickler, 2018, Genomic landscape of cell-free DNA in patients with colorectal cancer, Cancer Discov., 8, 164, 10.1158/2159-8290.CD-17-1009 Frenel, 2015, Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration, Clin. Cancer Res., 21, 4586, 10.1158/1078-0432.CCR-15-0584 Xia, 2015, Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer, Oncotarget, 6, 16411, 10.18632/oncotarget.3845 Murtaza, 2013, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA, Nature, 497, 108, 10.1038/nature12065 Abbosh, 2017, Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution, Nature, 545, 446, 10.1038/nature22364 Bhang, 2015, Studying clonal dynamics in response to cancer therapy using high-complexity barcoding, Nat. Med., 21, 440, 10.1038/nm.3841 Roerink, 2018, Intra-tumour diversification in colorectal cancer at the single-cell level, Nature, 556, 457, 10.1038/s41586-018-0024-3 Baslan, 2017, Unravelling biology and shifting paradigms in cancer with single-cell sequencing, Nat. Rev. Cancer, 17, 557, 10.1038/nrc.2017.58 Biankin, 2015, Patient-centric trials for therapeutic development in precision oncology, Nature, 526, 361, 10.1038/nature15819 Gao, 2016, Punctuated copy number evolution and clonal stasis in triple-negative breast cancer, Nat. Genet., 48, 1119, 10.1038/ng.3641 Navin, 2011, Tumour evolution inferred by single-cell sequencing, Nature, 472, 90, 10.1038/nature09807 Shaffer, 2017, Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance, Nature, 546, 431, 10.1038/nature22794 Schwarz, 2015, Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis, PLoS Med., 12, 10.1371/journal.pmed.1001789 Tang, 2015, Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing, Oncotarget, 6, 37169, 10.18632/oncotarget.5951 Bardelli, 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer, Cancer Discov., 3, 658, 10.1158/2159-8290.CD-12-0558 Castellarin, 2013, Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease, J. Pathol., 229, 515, 10.1002/path.4105 Gundem, 2015, The evolutionary history of lethal metastatic prostate cancer, Nature, 520, 353, 10.1038/nature14347 Misale, 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, 486, 532, 10.1038/nature11156 Guernet, 2016, CRISPR-barcoding for intratumor genetic heterogeneity modeling and functional analysis of oncogenic driver mutations, Mol. Cell, 63, 526, 10.1016/j.molcel.2016.06.017 Davis, 2017, Tumor evolution: linear, branching, neutral or punctuated?, Biochim. Biophys. Acta Rev. Cancer, 1867, 151, 10.1016/j.bbcan.2017.01.003 Fidler, 2003, The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited, Nat. Rev. Cancer, 3, 453, 10.1038/nrc1098 Horning, 2017, A new cancer ecosystem, Science, 355, 1103, 10.1126/science.aan1295 Kim, 2016, Gene–gene interactions in gastrointestinal cancer susceptibility, Oncotarget, 7, 67612, 10.18632/oncotarget.11701 McDonald, 2017, Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening, Cell, 170, 577, 10.1016/j.cell.2017.07.005 Zhao, 2017, Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer, Nature, 542, 484, 10.1038/nature21357 Kuzmin, 2018, Systematic analysis of complex genetic interactions, Science, 360, 1729, 10.1126/science.aao1729 Sahni, 2015, Widespread macromolecular interaction perturbations in human genetic disorders, Cell, 161, 647, 10.1016/j.cell.2015.04.013 Bhawe, 2018, Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression, Cell. Oncol., 41, 465, 10.1007/s13402-018-0395-3 van Dijk, 2018, Recovering gene interactions from single-cell data using data diffusion, Cell, 174, 716, 10.1016/j.cell.2018.05.061 Rheinbay, 2017, Recurrent and functional regulatory mutations in breast cancer, Nature, 547, 55, 10.1038/nature22992 Cleary, 2014, Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers, Nature, 508, 113, 10.1038/nature13187 Fellmann, 2017, Cornerstones of CRISPR-Cas in drug discovery and therapy, Nat. Rev. Drug Discov., 16, 89, 10.1038/nrd.2016.238 Anastasiadou, 2018, Non-coding RNA networks in cancer, Nat. Rev. Cancer, 18, 5, 10.1038/nrc.2017.99 Yi, 2017, Functional variomics and network perturbation: connecting genotype to phenotype in cancer, Nat. Rev. Genet., 18, 395, 10.1038/nrg.2017.8 Cowen, 2017, Network propagation: a universal amplifier of genetic associations, Nat. Rev. Genet., 18, 551, 10.1038/nrg.2017.38 Scott, 2016, Small molecules, big targets: drug discovery faces the protein–protein interaction challenge, Nat. Rev. Drug Discov., 15, 533, 10.1038/nrd.2016.29 Huttlin, 2017, Architecture of the human interactome defines protein communities and disease networks, Nature, 545, 505, 10.1038/nature22366 Altorki, 2019, The lung microenvironment: an important regulator of tumour growth and metastasis, Nat. Rev. Cancer, 19, 9, 10.1038/s41568-018-0081-9 Angelova, 2018, Evolution of metastases in space and time under immune selection, Cell, 175, 751, 10.1016/j.cell.2018.09.018 Li, 2017, The fundamental advantages of temporal networks, Science, 358, 1042, 10.1126/science.aai7488 Lee, 2018, Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy, Nat. Genet., 50, 1399, 10.1038/s41588-018-0209-6 Crick, 1970, Central dogma of molecular biology, Nature, 227, 561, 10.1038/227561a0 Wan, 2017, Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat. Rev. Cancer, 17, 223, 10.1038/nrc.2017.7 Shen, 2018, Sensitive tumour detection and classification using plasma cell-free DNA methylomes, Nature, 563, 579, 10.1038/s41586-018-0703-0 Crick, 1958, On protein synthesis, Symp. Soc. Exp. Biol., 12, 138 Rask-Andersen, 2011, Trends in the exploitation of novel drug targets, Nat. Rev. Drug Discov., 10, 579, 10.1038/nrd3478 Gerstein, 2012, Architecture of the human regulatory network derived from ENCODE data, Nature, 489, 91, 10.1038/nature11245 Roukos, 2014, Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery, Curr. Pharm. Des., 20, 11, 10.2174/138161282001140113122438 Gonda, 2015, Directly targeting transcriptional dysregulation in cancer, Nat. Rev. Cancer, 15, 686, 10.1038/nrc4018 Roukos, 2016, Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies, Drug Discov. Today, 21, 663, 10.1016/j.drudis.2016.02.008 Rambow, 2018, Toward minimal residual disease-directed therapy in melanoma, Cell, 174, 843, 10.1016/j.cell.2018.06.025